Amgen

News

Third indication beckons for Amgen's Uplizna

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.

News

NICE backs consolidation use of Blincyto in leukaemia

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

News

Amgen picks up key colorectal cancer okay for KRAS drug

Can a new FDA approval in colorectal cancer kickstart sales growth for Amgen's KRAS inhibitor Lumakras?

News

Sling shoots at thyroid eye disease with its oral therapy

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Amgen's big reveal of obesity data falls a little flat

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations

Third indication beckons for Amgen's Uplizna

NICE backs consolidation use of Blincyto in leukaemia

Amgen picks up key colorectal cancer okay for KRAS drug

Sling shoots at thyroid eye disease with its oral therapy

11 blockbuster drugs to look out for in 2025

Amgen's big reveal of obesity data falls a little flat

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Amgen

Editor's Picks